Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Spanish reimbursement system

- PMLiVE

New WHO initiative to prioritise endemic pathogens for vaccine development

Value profiles of 16 pathogens with vaccines in clinical development will be featured

- PMLiVE

Message from the Women in Medicine™ Summit: “Be the Change You Want to See”

What are some of the biggest gaps that women still face in healthcare today?“So many I could talk for hours!” says Shikha Jain, MD, FACP, President, CEO, Founder Women in...

Medscape Education

- PMLiVE

Best practices for building an effective scientific communications platform

By Luis Perez

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

- PMLiVE

Takeda’s enzyme replacement therapy approved by FDA for rare blood clotting disorder

The ultra-rare inherited disease is estimated to affect fewer than 1,000 people in the US

- PMLiVE

GSK’s momelotinib recommended by CHMP to treat myelofibrosis patients with anaemia

About 40% of patients have moderate-to-severe anaemia at the time of diagnosis

- PMLiVE

Redefining medical communications in the age of omnichannel engagement

By Chris Hall

- PMLiVE

Takeda’s Fruzaqla receives FDA approval for metastatic colorectal cancer

More than 150,000 new cases of colorectal cancer will be diagnosed in the US in 2023

- PMLiVE

Valneva’s chikungunya vaccine approved by FDA for adults at increased exposure risk

The decision makes Ixchiq, which is administered as a single injection, the world's first licensed vaccine against the mosquito-borne disease

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links